Monday, August 05, 2019 2:54:29 PM
Conversely, where will the p/s be when Elite does exactly as Nasrat indicated, shows the increase in revenues that put it on track for all time highs?
But here is the thing that a sober analysis must consider...
Elite was within 6 days of the end of Q1 2020 when Nasrat made that forward looking statement. As the company has planned manufacturing to meet the commercialization needs, Nasrat would be well aware of the sales to that point. How is it possible he would make a statement about Q1 2020 revenues doubling those of Q4 2019 revenues if not absolutely certain? In fact, with his general counsel reviewing all PR and CC scripts, it is fair to say that if there were any issues with the projections Nasrat made, then legal counsel would not have approved it.
Because? If he gave approval and it was not true, the GC might be guilty of malpractice and Nasrat might find himself in legal jeopardy. So no, Elite will not miss the projection because this is not about an external force (think FDA) that influences the matter. This is all about Elite achieving what was stated. And, OBTW: there was no promise. Rather, it was a statement of belief based on the evidence. Nothing more, nothing less.
But here is the thing that a sober analysis must consider...
Elite was within 6 days of the end of Q1 2020 when Nasrat made that forward looking statement. As the company has planned manufacturing to meet the commercialization needs, Nasrat would be well aware of the sales to that point. How is it possible he would make a statement about Q1 2020 revenues doubling those of Q4 2019 revenues if not absolutely certain? In fact, with his general counsel reviewing all PR and CC scripts, it is fair to say that if there were any issues with the projections Nasrat made, then legal counsel would not have approved it.
Because? If he gave approval and it was not true, the GC might be guilty of malpractice and Nasrat might find himself in legal jeopardy. So no, Elite will not miss the projection because this is not about an external force (think FDA) that influences the matter. This is all about Elite achieving what was stated. And, OBTW: there was no promise. Rather, it was a statement of belief based on the evidence. Nothing more, nothing less.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
